Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.
Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.
Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

开始日期2024-09-30

申办/合作机构

AbbVie, Inc.

NCT06414044 / RecruitingN/AIIT

STudio Osservazionale Sull'Efficacia, Sicurezza e tollerabilità di Atogepant in Pazienti Real Life Affetti da Emicrania in Italia (Studio STAR)

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of atogepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

开始日期2024-05-09

申办/合作机构

University of Florence

[+8]

CTR20240519 / Recruiting临床3期

一项评价 Atogepant 用于偏头痛急性发作治疗的疗效、安全性、耐受性和效果一致性的随机、双盲、安慰剂对照、多次发作研究（ECLIPSE）

评价Atogepant单次给药相比安慰剂治疗单次偏头痛急性发作的疗效。评价Atogepant治疗偏头痛急性单次发作和多次发作的安全性和耐受性，并评价治疗多次发作的效果一致性。

开始日期2024-04-16

申办/合作机构

Forest Laboratories Ireland Ltd.

[+2]

100 项与阿托吉泮相关的临床结果

登录后查看更多信息

100 项与阿托吉泮相关的转化医学

登录后查看更多信息

100 项与阿托吉泮相关的专利（医药）

登录后查看更多信息

102

项与阿托吉泮相关的文献（医药）

2024-08-01·Brain : a journal of neurology

Novel insight into atogepant mechanisms of action in migraine prevention

Article

作者: Brin, Mitchell ; Dabruzzo, Brett ; Broide, Ron ; Melo-Carrillo, Agustin ; Strassman, Andrew M ; Burstein, Rami ; Adams, Aubrey

Abstract:

Recently, we showed that while atogepant—a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist—does not fully prevent activation of meningeal nociceptors, it significantly reduces a cortical spreading depression (CSD)-induced early response probability in C fibres and late response probability in Aδ fibres. The current study investigates atogepant effect on CSD-induced activation and sensitization of high threshold (HT) and wide dynamic range (WDR) central dura-sensitive trigeminovascular neurons.In anaesthetized male rats, single-unit recordings were used to assess effects of atogepant (5 mg/kg) versus vehicle on CSD-induced activation and sensitization of HT and WDR trigeminovascular neurons.Single cell analysis of atogepant pretreatment effects on CSD-induced activation and sensitization of central trigeminovascular neurons in the spinal trigeminal nucleus revealed the ability of this small molecule CGRP receptor antagonist to prevent activation and sensitization of nearly all HT neurons (8/10 versus 1/10 activated neurons in the control versus treated groups, P = 0.005). In contrast, atogepant pretreatment effects on CSD-induced activation and sensitization of WDR neurons revealed an overall inability to prevent their activation (7/10 versus 5/10 activated neurons in the control versus treated groups, P = 0.64). Unexpectedly however, in spite of atogepant’s inability to prevent activation of WDR neurons, it prevented their sensitization (as reflected their responses to mechanical stimulation of the facial receptive field before and after the CSD).Atogepant’ ability to prevent activation and sensitization of HT neurons is attributed to its preferential inhibitory effects on thinly myelinated Aδ fibres. Atogepant’s inability to prevent activation of WDR neurons is attributed to its lesser inhibitory effects on the unmyelinated C fibres. Molecular and physiological processes that govern neuronal activation versus sensitization can explain how reduction in CGRP-mediated slow but not glutamate-mediated fast synaptic transmission between central branches of meningeal nociceptors and nociceptive neurons in the spinal trigeminal nucleus can prevent their sensitization but not activation.

2024-08-01·Clinical Pharmacology in Drug Development

Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study

Article

作者: Wangsadipura, Veronica ; Borbridge, Lisa ; Boinpally, Ramesh

Abstract:

Atogepant, an oral calcitonin gene‐related peptide receptor antagonist, is approved for the preventive treatment of migraine. Atogepant is a substrate of P‐glycoprotein (P‐gp), breast cancer resistance protein, organic anion transporting polypeptide transporters, and cytochrome P450 (CYP)3A4 and 2D6. Quinidine is a strong P‐gp and CYP2D6 inhibitor. A phase 1 open‐label study evaluated the effect of P‐gp and CYP2D6 inhibition by quinidine on the pharmacokinetics of atogepant, and the safety and tolerability of atogepant and quinidine gluconate (QG) when co‐administered and when given alone in 33 healthy adults. There was no significant change in the atogepant maximum plasma concentration with QG co‐administration. The overall systemic exposure, the area under the plasma concentration‐time curve (from time 0 to time t or to infinity), of atogepant increased by 25% when co‐administered with QG. However, such an increase was not considered clinically relevant. Atogepant did not alter the mean plasma concentration of quinidine at steady state. The incidence of treatment‐emergent adverse events (TEAEs) was highest when QG was administered alone (42.4%), which was primarily due to QT prolongation. Most TEAEs reported were mild in severity and resolved within 1‐2 days. Co‐administration of atogepant with QG did not result in any unexpected tolerability findings in this phase 1 study in healthy participants. The increase in atogepant exposure during QG co‐administration could be due to inhibition of CYP2D6 (a minor contributor to atogepant clearance) as well as inhibition of P‐gp.

2024-07-23·NEUROLOGY

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial

Article

作者: Liu, Yingyi ; Smith, Jonathan H ; Dabruzzo, Brett ; Sakai, Fumihiko ; Holle-Lee, Dagny ; Ashina, Sait ; Goadsby, Peter J ; Gandhi, Pranav ; Neel, Brian ; Friedman, Deborah I ; Trugman, Joel M ; Demarquay, Genevieve

BACKGROUND AND OBJECTIVES:

Atogepant is an oral, calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine. We evaluated the efficacy of atogepant for the preventive treatment of chronic migraine (CM) in participants with and without acute medication overuse.

METHODS:

This subgroup analysis of the phase 3, 12-week, randomized, double-blind, placebo-controlled PROGRESS trial evaluated adults with a ≥1-year history of CM, ≥15 monthly headache days (MHDs), and ≥8 monthly migraine days (MMDs) during the 4-week baseline period. Participants were randomized (1:1:1) to placebo, atogepant 30 mg twice daily (BID), or atogepant 60 mg once daily (QD) for 12 weeks and were analyzed by acute medication overuse status (triptans/ergots for ≥10 days per month, simple analgesics for ≥15 days per month, or combinations of triptans/ergots/simple analgesics for ≥10 days per month). Outcomes included change from baseline in mean MMDs, MHDs, and monthly acute medication use days; ≥50% reduction in mean MMDs across 12 weeks; and patient-reported outcome (PRO) measures.

RESULTS:

Of 755 participants in the modified intent-to-treat population, 500 (66.2%) met baseline acute medication overuse criteria (placebo, n = 169 [68.7%]; atogepant 30 mg BID, n = 161 [63.6%]; atogepant 60 mg QD, n = 170 [66.4%]). The least squares mean difference (LSMD) (95% CI) from placebo in MMDs was -2.7 (-4.0 to -1.4) with atogepant 30 mg BID and -1.9 (-3.2 to -0.6) with atogepant 60 mg QD. Mean MHDs (LSMD [95% CI] -2.8 [-4.0 to -1.5] and -2.1 [-3.3 to -0.8]) and mean acute medication use days (LSMD [95% CI] -2.8 [-4.1 to -1.6] and -2.6 [-3.9 to -1.3]) were reduced and a higher proportion of participants achieved ≥50% reduction in MMDs (odds ratio [95% CI] 2.5 [1.5-4.0] and 2.3 [1.4-3.7]) with atogepant 30 mg BID and atogepant 60 mg QD. There was a 52.1%-61.9% reduction in the proportion of atogepant-treated participants meeting acute medication overuse criteria over 12 weeks. Atogepant improved PRO measures. Similar results were observed in the subgroup without acute medication overuse.

DISCUSSION:

Atogepant was effective in participants with CM, with and without acute medication overuse, as evidenced by reductions in mean MMDs, MHDs, and acute medication use days; reductions in the proportion of participants meeting acute medication overuse criteria; and improvements in PROs.

TRIAL REGISTRATION INFORMATION:

ClinicalTrials.gov NCT03855137. Submitted: February 25, 2019; first patient enrolled: March 11, 2019. clinicaltrials.gov/ct2/show/NCT03855137.

CLASSIFICATION OF EVIDENCE:

This study provides Class II evidence that atogepant reduces mean MMDs, MHDs, and monthly acute medication use days in adult patients with or without medication overuse.

146

项与阿托吉泮相关的新闻（医药）

2024-09-23

·GBIHealth

全球医药企业主要管线进度更新（上） -2024H1

在GLP-1横扫一切的强势驱动下，无论是业绩和市值，还是各自的产品布局，全球大药企都在经历深刻的变局，甚至可以说进行了颠覆性的重排，仅是下面这张摘要图与半年前相比就有不小的差异。本文追踪了2024H1全球医药企业的主要管线进度，涵盖礼来、诺和诺德、强生、默沙东等11家全球医药企业。注：因篇幅原因上篇包含1-5家药企，下篇将继续为念呈现：罗氏ROG、阿斯利康AZN、诺华NVS、辉瑞PFE、赛诺菲SNY、百时美施贵宝BMY。礼来LLY LLY的业绩确实逆天，尤其2024年第二季度的收入肉眼可见跳了一大格、两年时间内几乎翻倍；而市值的成长却远不止翻倍，仅今年就从$500b飚到最高$850b，虽然近期略有回落，但自季报出炉两个交易日又怒涨了$100b，目前哪怕按公司全年业绩指引的上限也是66x市盈率…… Tirzepatide这个季度的极致爆发已经基本上奠定了与Semaglutide对决的后续基调，攻守之势异也。Mounjaro和Zepbound分别环比增长71%和140%，单季度销售额总共达到$4.3b；与之相比，S药已经连续两个季度走平，目前单季度T药已经追到S药的65%水平。在这个超级引擎的驱动下，公司业绩一路打破预期，几乎每个季度都在调高全年指引。管线的攻城略地仍在发力：在万众瞩目的代谢板块，Tirzepatide先后公布了OSA三期临床、HFpEF三期临床、MASH二期临床等结果，长效胰岛素也公布了两个三期临床结果，Amylin激动剂启动二期临床，Lp(a) siRNA药物Lepodisiran启动三期临床，但Empagliflozin的心衰三期临床也未能达到终点；阿尔茨海默药物Donanemab终于获得FDA批准；自免板块，以$3.2b 购Morphic获得小分子α4β7抑制剂，IL-13单抗Lebrikizumab在FDA给出CRL后重新提交上市申请，IL23p19单抗Mirikizumab在提交CD适应症上市申请后公布完整三期临床数据；肿瘤板块，去年收购Emergence得到的Nectin-4 ADC管线ETx-22进入临床，CDK4/6抑制剂Abemaciclib连续在mCRPC和HSPC等适应症的三期临床中失败。诺和诺德NVO NVO自从Semaglutide打开减重之门以来，连续两年多的股价连升势头终于被中断，从最高点$650b左右显著回调到$550b以下，特别是在中报公布当天大跌8%，业绩增长的步伐放缓恰恰与此前星辰大海的预期形成较大落差。近期正是两大减肥神药Semaglutide和Tirzepatide对决的天王山之战，面对T药的冲击和逼近，S药自身开始走平，连续两个季度环比增长几乎停滞，而对手T药这个季度简直是要疯、环比近乎要翻倍，二者之间的差距在急速缩小。最重要的研发进展当然还是围绕着Semaglutide，近期公布CKD的三期临床结果并提交该适应症的上市申请，口服25mg剂型的三期临床也公布积极结果，然而 HFpEF的上市申请被撤回、可能被隔壁LLY反超进度；Icodec虽然在欧洲、中国、日本陆续获批，但美国FDA却给了CRL拒绝批准；IcoSema复方公布了两个T2D三期临床结果；血友病双抗Mim8终于公布了三期临床结果；以€1.025b收购Cardior，获得一款靶向miR-132的ASO药物CDR-132L，目前正在开展治疗心衰的二期临床。强生JNJ JNJ在持续两年多不温不火的业绩之后，医药部分的季度收入首次有了比较可观的增长、到了$14.5b，但市值依然回不到$400b大关，与GLP-1双雄LLY和NOVO的距离仍在越拉越大。强生医药板块的业绩在大药企中还是相当稳健，其中Ustekinumab和Daratumumab上市十多年还迭创新高，Guselkumab和Macitentan+Selexipag也在高位维持稳步增长，CAR-T药物Cilta-cel在产能瓶颈缓解后开始重拾增长，但Ibrutinib、Infliximab、Abiraterone、Paliperidone等曾经的超重磅品种确实老态渐显。研发方面也有多项重磅突破：Cilta-cel凭借CARTITUDE-4三期临床的惊艳结果获批2-4LMM适应症，EGFR/cMET双抗Amivantamab获批治疗EGFRExon20插入突变的1L NSCLC，FcRn单抗Nipocalimab公布重症肌无力三期临床达到主要临床终点，靶向IL-23R的口服多肽JNJ-2113公布了52周治疗斑块状银屑病的二期试验结果，OX2R拮抗剂Seltorexant公布了伴随失眠症状的重度抑郁症三期临床结果，Macitentan与Tadalafil每日一次口服复方制剂获批治疗PAH；此外，公司近期连续完成自免领域的资产收购，包括从Numab以$1.25b收购将进入二期的IL4Rα/IL31双抗NM26，以及以$850m收购Proteologix获得将进入一期的IL13/TSLP双抗PX128和尚在临床前的IL13/IL22双抗PX130。当然，近期最有想象空间的大事件，就属传奇生物的收购传闻，潜在收购方（也应该是最顺理成章的人选）便是JNJ本尊。默沙东MRK MRK在新冠药回撤后经历过一小段业绩和股价的波动，但凭借K药坐稳药王且持续增长，市值原本稳稳站在$300b以上，然而就在中报公布当天大跌10%，主要是HPV疫苗在中国因反腐等原因大幅不及预期。研发进展除了围绕K药的各种扩适应症和联用方案以外，已经展现出更多的未来增长来源：PAH药物Sotatercept和21价肺炎疫苗V116（Capvaxive）先后获得 FDA批准，RSV抗体Clesrovimab公布了针对婴儿的Ph2b/3期临床达到主要和次要临床终点，新一代HIV药物Islatravir公布了联用Lenacapavir的二期临床结果，靶向B7H3的DS-7300启动SCLC三期临床，靶向CDH6的DS-6000启动了PROC 的2/3期临床；以$1.3b首付款+$1.7b里程碑收购EyeBio，获得一款靶向LRP5 两个表位和FZD4的三抗；坏消息包括，HER3 ADC管线U3-1402的上市申请被 FDA因生产原因拒绝，Olaparib的NSCLC三期临床和TIGIT单抗Vibostolimab联用K药治疗黑色素瘤的三期临床都遭遇失败。艾伯维ABBV 艾伯维虽然遭遇Adalimumab和Ibrutinib两大超重磅品种的下滑，所幸Risankizuma、Upadacitinib、Venetoclax、Cariprazine几个新生代贡献一定的增量，整体业绩才算没有太崩坏，外加通过收购获得ADC和精神疾病领域等重要管线，因此市值近期成功突破到$300b以上。自免板块主要仍以现有重磅的适应症扩展为主，包括Risankizumab获批UC适应症，Upadacitinib公布与Dupilumab头对头的特应性皮炎3/4期临床试验结果、公布治疗巨细胞动脉炎的三期临床结果并提交上市申请，另外还以$210m收购了Landos获得一款治疗IBD的NLRX1激动剂NX-13；此外，偏头痛药物Atogepant公布预防适应症的长期临床结果，CD20/CD3双抗Epcoritamab获批3L+ FL适应症。注：因篇幅原因上篇包含1-5家药企，下篇将继续为念呈现：罗氏ROG、阿斯利康AZN、诺华NVS、辉瑞PFE、赛诺菲SNY、百时美施贵宝BMY。

临床3期siRNA并购临床2期

2024-09-13

·FiercePharma

Tonix questions efficacy of oral migraine drugs in awareness campaign

Tonix is set to launch a disease education website to explain the link between gastroparesis and migraine. Tonix Pharmaceuticals is trying to start a conversation about a potential shortcoming of oral migraine drugs, kicking off a national campaign to raise awareness of a condition that can affect absorption.The company’s commercial subsidiary, Tonix Medicines, markets two formulations of sumatriptan for use in migraine. Sumatriptan was approved more than 30 years ago. Dr. Reddy’s Laboratories received FDA approval for an injectable formulation, Zembrace SymTouch, in 2016 and a nasal spray version in 2019. Tonix acquired the products in 2023.Facing off against oral drugs such as AbbVie’s Ubrelvy, Tonix is seeking to raise awareness of potential benefits of nasal and injectable formulations with the “Does Your Migraine Pill Work Every Time?” Tonix launched the campaign at the PAINWeek 2024 National Conference in Las Vegas.The question posed in the educational campaign reflects studies showing a link between gastroparesis and migraine. Gastroparesis is defined by the delayed emptying of the contents of the stomach into the intestine, potentially causing symptoms such as vomiting. Studies show some patients have migraine and gastroparesis at the same time. If that happens, gastroparesis could limit the absorption of oral drugs. “Non-oral migraine medications, such as injectables and nasal sprays, do not rely on the digestive system to be absorbed and can offer the potential for faster relief from migraine symptoms in as little as 10 minutes,” the University of Texas Southwestern Medical Center’s Deborah Friedman, M.D., said in a statement. Friedman encourages patients and doctors to discuss adding non-oral options to their treatment plans.Tonix is set to launch a disease education website to explain the link between gastroparesis and migraine and why oral medicines may not work. The company has also scheduled a webinar on the topic for next week.Spreading the word about situations in which oral drugs may be ineffective could benefit Tonix’s drugs, sales of which totaled $2.2 million in the second quarter. The figure makes Tonix a small player in the migraine market. Pfizer reported $356 million in sales of Nurtec ODT, which dissolves in the mouth, over the same period. AbbVie’s Ubrelvy and Qulipta generated a combined $381 million.

上市批准

2024-09-10

·FiercePharma

AbbVie's Ubrelvy to be top migraine seller in 2033 as total market to hit $16B-plus across biggest pharma countries

Newer meds are coming up against reimbursement issues against older, cheaper migraine drugs. AbbVie’s migraine drug Ubrelvy (ubrogepant) is slated to be the top-selling drug in the migraine space in 2033 across the seven bigger pharma markets as total spend across those countries are set to rake in $16.4 billion.That’s according to new migraine market figures out by analysts at GlobalData. They see Ubrelvy hitting sales of $1.07 billion in 2033, primarily because it has one of the later patent expiry dates in what has become a large and highly competitive migraine market.Drug treatments and preventive meds include the likes of AbbVie’s other migraine meds, Qulipta and Botox, as well as Pfizer’s Nurtec ODT, Lundbeck’s Vyepti, Eli Lilly’s Emgality and Reyvow, and Teva’s Ejovy. There are also a lot of older, cheaper drugs on the market. The seven markets, often used by GlobalData for these figures, comprise the U.S., France, Germany, Italy, Spain, the U.K. and Japan.Last year, these countries saw their total combined migraine market worth $9.2 billion, but this will swell to $16.4 billion by 2033 at a compound annual growth rate of 6%, according to GlobalData.The analysts see the growth as being “primarily driven by increased prescription of calcitonin gene-related peptide (CGRP) antagonists—monoclonal antibodies (mAbs) for prevention and oral gepants for both acute and preventive treatment,” they said in the report.Philippa Salter, managing neurology analyst at GlobalData, notes, however, that reimbursement issue from payers for newer meds is an issue that is restricting some growth of the market.“When compared with the cheap generic drugs dominating current standard-of-care drug classes, such as triptans in the acute setting, and non-migraine-specific treatment classes, such as antidepressants, anticonvulsants, and beta blockers for prevention, CGRP antagonists have significantly higher annual costs of therapy.“However, the growth in these drug classes will be limited by reimbursement restrictions, as well as the patent expiries of all these branded drugs towards the end of the forecast period.”GlobalData also scanned the horizon and sees seven products in the late-stage biopharma pipeline that could be approved across some or all the seven big countries up to 2033, something that “will be another driver of growth for the market.”The analysts note, however, that “there is a lack of novelty among these products,” and the majority focus on reformulations and combinations, “meaning that the triptans will not be displaced as first-line acute therapies.”

专利到期

100 项与阿托吉泮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11313	阿托吉泮	-	DB16098

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	AbbVie, Inc.	2021-09-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
无先兆偏头痛	临床3期	美国	Allergan Ltd. (Ireland)	2016-09-06
急性偏头痛	临床申请批准	中国	AbbVie, Inc.	2023-12-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03855137 (PROGRESS, Pubmed)	临床3期	继发性头痛症	755	Atogepant 30 mg BID	鹽蓋願膚顧壓願夢選網(選構選窪獵艱壓壓衊鑰) = 構積餘齋築範製壓構選糧壓夢廠鹽網獵醖鹹遞 (構鹽顧網築淵鬱餘鹽夢, -4.0 ~ -1.5) 更多	积极	2024-07-23
NCT03777059 \| NCT03700320 (ADVANCE, Pubmed)	临床3期	偏头痛 calcitonin gene-related peptide receptor	-	Atogepant 10 mg	蓋遞遞襯壓廠鬱蓋淵艱(夢網襯觸壓簾鏇鬱製鑰) = 壓鹽鬱鑰構艱鹽選糧顧網鏇鹽艱製範膚襯鬱廠 (製顧鑰憲淵簾構醖構鏇 ) 更多	积极	2024-05-21
				Atogepant 30 mg	蓋遞遞襯壓廠鬱蓋淵艱(夢網襯觸壓簾鏇鬱製鑰) = 夢網顧簾憲製膚顧衊顧網鏇鹽艱製範膚襯鬱廠 (製顧鑰憲淵簾構醖構鏇 ) 更多
NCT04740827 \| NCT03855137 \| NCT04686136 (3101-312-002, PRNewswire) 人工标引	临床3期	偏头痛	-	Atogepant 60 mg	夢積鹽襯選淵鏇艱餘遞(積獵鏇簾願衊製齋積憲) = 醖築廠膚艱蓋醖衊鹽夢範憲獵鬱齋憲憲鬱繭構 (鏇夢構艱壓壓糧鏇願顧 ) 更多	积极	2024-04-12
NCT03777059 \| NCT03939312 \| NCT03700320 \| NCT02848326 (Pubmed)	N/A	偏头痛	1,550	Atogepant	遞醖構衊鬱壓鹽積鏇繭(蓋簾積鹹鑰壓願構遞淵) = 蓋蓋網構鬱壓鬱夢衊製顧鏇簾積簾衊選願積醖 (鬱糧遞鬱壓壓襯餘鹹構 ) 更多	积极	2024-03-11
				Placebo	遞醖構衊鬱壓鹽積鏇繭(蓋簾積鹹鑰壓願構遞淵) = 壓製衊艱襯顧夢構夢鬱顧鏇簾積簾衊選願積醖 (鬱糧遞鬱壓壓襯餘鹹構 ) 更多
NCT04740827 (ELEVATE, CTgov)	临床3期	偏头痛	315	Placebo (Placebo)	鬱觸醖醖鬱憲網襯齋窪(範窪鏇獵艱構夢鏇願夢) = 簾窪鑰顧醖築遞膚襯選顧襯繭壓鹽願壓繭窪鏇 (艱艱鹽願夢遞夢淵淵繭, 積窪繭網壓糧膚襯鏇獵 ~ 鑰鹽壓鹹蓋淵願選鏇襯) 更多	-	2023-09-21
				Atogepant 60 mg (Atogepant 60 mg)	鬱觸醖醖鬱憲網襯齋窪(範窪鏇獵艱構夢鏇願夢) = 襯簾築範醖遞鹽醖遞艱顧襯繭壓鹽願壓繭窪鏇 (艱艱鹽願夢遞夢淵淵繭, 艱顧壓鹹糧鹹淵艱憲網 ~ 蓋壓艱願鑰壓壓糧積選) 更多
NCT03700320 (Pubmed \| Cephalalgia)	临床3期	偏头痛	744	Atogepant 60 mg once-daily	願淵顧夢齋網襯願顧鑰(醖衊餘夢窪衊簾艱壓構) = 齋襯窪繭壓壓選鏇夢齋鏇襯繭壓繭網鏇鹹憲範 (夢觸鹽窪範鹹夢繭觸鏇, 28.16 ~ 31.87)	积极	2023-09-01
PROGRESS (EMA) 人工标引	N/A	偏头痛	506	AQUIPTA 60mg	選選選遞製網獵選壓醖(糧窪簾襯構衊壓窪齋廠) = 壓膚齋襯構鏇蓋鏇簾齋艱範願蓋醖鹽糧醖糧窪 (衊築糧鏇積築鹹獵積觸 ) 更多	积极	2023-08-25
				Placebo	選選選遞製網獵選壓醖(糧窪簾襯構衊壓窪齋廠) = 壓膚積積積餘構獵鑰壓艱範願蓋醖鹽糧醖糧窪 (衊築糧鏇積築鹹獵積觸 ) 更多
ADVANCE (EMA) 人工标引	N/A	偏头痛	442	AQUIPTA 60mg	鹽遞範蓋積築顧窪構糧(範膚顧廠鑰膚觸壓選夢) = 廠遞淵鏇鏇鑰鹹範醖製遞繭淵蓋壓觸選構獵鬱 (醖醖壓願淵淵憲膚艱鏇 ) 更多	积极	2023-08-25
				Placebo	鹽遞範蓋積築顧窪構糧(範膚顧廠鑰膚觸壓選夢) = 選膚廠鏇糧窪繭觸壓艱遞繭淵蓋壓觸選構獵鬱 (醖醖壓願淵淵憲膚艱鏇 ) 更多
NCT04829747 (CTgov)	临床3期	偏头痛	3	Atogepant	範鹹淵艱願醖獵襯鬱築(鹽膚鏇構構遞範遞餘鹹) = 網齋構獵網遞壓製遞鏇齋醖夢繭齋淵膚襯觸鑰 (窪艱鬱網醖襯鹽餘廠簾, 鏇積選鑰觸願顧範壓築 ~ 廠築顧壓網鬱廠餘餘鑰) 更多	-	2023-05-24
NCT03855137 (PROGRESS, AAN2023)	临床3期	偏头痛 age \| smoking \| body mass index ... 更多	773	Atogepant 30mg twice-daily	鏇糧鬱願艱遞鬱窪憲蓋(壓糧積廠遞醖鑰顧構壓) = CV-TEAEs occurred at low frequencies among participants with ≥2 CV-RFs (placebo: 3/116[2.6%]; pooled atogepant: 9/261[3.4%]), and none were serious. Treatment-related CV-TEAEs included palpitations (n=2) and increased blood pressure (n=1) in the pooled atogepant group (all 30mg twice-daily) and flushing (n=1) in the placebo group. Palpitations led to 1 discontinuation (assessed as not treatment-related) in the pooled atogepant group. 憲顧鑰獵鬱遞鑰壓構餘 (憲齋膚壓積齋網齋構網 )	积极	2023-04-25
				Placebo